CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 325 enrolled
Drug / intervention
XP13512 600MG +2 moredrug
Likely dose
XP13512 600MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00365352
NCT00365352Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.

XenoPort, Inc.·interventional·Posted Aug 17, 2006·Updated Jul 22, 2013

In Brief

A Phase 3 clinical trial evaluating XP13512 600MG, XP13512 1200MG, and 1 other intervention for Restless Legs Syndrome. Completed, enrolled 325 participants.

Detailed Summary

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 17, 2006
Enrollment StartAug 1, 2006
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.9 years ago

Interventions

XP13512 600MGdrug

XP13512 600MG ONCE DAILY

XP13512 1200MGdrug

XP13512 1200MG ONCE DAILY

PLACEBOdrug

PLACEBO ONCE DAILY